Tom W J Huizinga Selected Research

acetyl 4-aminosalicylic acid

1/2022	IgG Anti-Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross-Sectional Study Encompassing ~1,500 Samples.
1/2021	Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis.
11/2020	Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis.
10/2019	N-Linked Glycans in the Variable Domain of IgG Anti-Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis.
11/2018	Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals.
1/2018	The B cell response to citrullinated antigens in the development of rheumatoid arthritis.
10/2016	Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis.
3/2012	Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity.
1/2011	The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA.
1/2010	Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tom W J Huizinga Research Topics

Disease

174	Rheumatoid Arthritis 04/2022 - 03/2003
45	Arthritis (Polyarthritis) 01/2021 - 02/2004
31	Inflammation (Inflammations) 11/2022 - 06/2004
15	Systemic Scleroderma (Systemic Sclerosis) 04/2022 - 10/2003
12	Osteoarthritis 12/2018 - 08/2003
8	Synovitis 05/2022 - 07/2010
8	Disease Progression 01/2022 - 07/2004
8	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 12/2004
8	Arthralgia (Joint Pain) 11/2018 - 04/2013
7	Pain (Aches) 12/2018 - 10/2008
7	Experimental Arthritis 01/2016 - 10/2004
6	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 04/2002
6	Necrosis 01/2020 - 02/2007
6	Infections 01/2016 - 11/2005
5	Fibrosis (Cirrhosis) 11/2020 - 10/2003
5	Neoplasms (Cancer) 01/2019 - 07/2003
3	Central Nervous System Lupus Vasculitis 01/2017 - 01/2006
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2016 - 06/2004
3	Wounds and Injuries (Trauma) 01/2013 - 03/2003
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 01/2017
2	Fatigue 06/2021 - 01/2015
2	Osteoporosis 01/2021 - 01/2016
2	Neutropenia 01/2018 - 09/2014
2	Tenosynovitis 12/2016 - 05/2015
2	Rheumatic Diseases (Rheumatism) 01/2016 - 02/2012
2	Lupus Nephritis 01/2016 - 11/2014
2	Chronic Disease (Chronic Diseases) 03/2014 - 09/2004
2	Rubella (German Measles) 03/2012 - 01/2007

Drug/Important Bio-Agent (IBA)

47	AntibodiesIBA 01/2021 - 02/2004
45	AutoantibodiesIBA 02/2022 - 02/2004
40	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2005
38	Anti-Citrullinated Protein AntibodiesIBA 01/2022 - 07/2004
30	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 04/2006
21	Antirheumatic Agents (DMARD)IBA 05/2022 - 10/2006
19	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 01/2002
18	AntigensIBA 01/2021 - 10/2004
14	Pharmaceutical PreparationsIBA 01/2019 - 05/2005
13	acetyl 4-aminosalicylic acidIBA 01/2022 - 01/2007
13	Immunoglobulin G (IgG)IBA 01/2022 - 01/2006
12	Peptides (Polypeptides)IBA 10/2016 - 07/2004
11	EpitopesIBA 01/2017 - 05/2005
10	Biological ProductsIBA 03/2021 - 08/2009
9	Rheumatoid FactorIBA 01/2019 - 01/2007
9	Interleukin-10 (Interleukin 10)IBA 08/2005 - 04/2002
8	Abatacept (Orencia)FDA Link 01/2020 - 09/2010
8	Prednisone (Sone)FDA LinkGeneric 01/2018 - 05/2009
7	Rituximab (Mabthera)FDA Link 01/2020 - 12/2007
7	CytokinesIBA 01/2016 - 01/2002
7	EnzymesIBA 08/2015 - 10/2003
7	cyclic citrullinated peptideIBA 04/2013 - 01/2005
6	amsonic acid (DAS)IBA 06/2021 - 06/2009
6	Immunoglobulin M (IgM)IBA 01/2021 - 01/2006
5	Etanercept (Enbrel)FDA Link 01/2020 - 02/2007
5	HLA-DRB1 Chains (HLA DRB1)IBA 10/2016 - 10/2005
5	HLA Antigens (Human Leukocyte Antigens)IBA 09/2015 - 05/2005
5	CollagenIBA 08/2015 - 07/2004
5	4-hexyloxyaniline (HOA)IBA 05/2014 - 07/2010
4	Polysaccharides (Glycans)IBA 02/2022 - 05/2011
4	Adalimumab (Humira)FDA Link 03/2021 - 02/2006
4	ametantrone (HAQ)IBA 01/2020 - 10/2013
4	sarilumabIBA 01/2020 - 09/2014
4	C-Reactive ProteinIBA 10/2016 - 09/2013
4	VimentinIBA 07/2011 - 08/2009
3	Biomarkers (Surrogate Marker)IBA 12/2021 - 02/2016
3	GlucocorticoidsIBA 01/2021 - 01/2016
3	tocilizumab (atlizumab)FDA Link 01/2020 - 09/2010
3	Infliximab (Remicade)FDA Link 01/2020 - 02/2007
3	Certolizumab Pegol FDA Link 01/2020 - 12/2012
3	Fibrinogen (Factor I)FDA Link 10/2014 - 01/2011
3	AdiponectinIBA 05/2014 - 07/2011
3	TNF Receptor-Associated Factor 1IBA 02/2011 - 09/2007
3	Messenger RNA (mRNA)IBA 06/2010 - 10/2003
3	Interleukin-1beta (Interleukin 1 beta)IBA 05/2005 - 05/2002
3	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 05/2005 - 05/2002
3	LipopolysaccharidesIBA 05/2005 - 10/2004
2	Immunoglobulin A (IgA)IBA 04/2022 - 11/2020
2	anticentromere antibodyIBA 12/2021 - 01/2021
2	Biosimilar PharmaceuticalsIBA 03/2021 - 01/2020
2	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA 01/2021 - 08/2017
2	AutoantigensIBA 01/2021 - 12/2004
2	anti-scl-70 autoantibodiesIBA 11/2020 - 05/2020
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2020 - 01/2018
2	tofacitinibIBA 01/2020 - 01/2016
2	Janus Kinase InhibitorsIBA 01/2020 - 01/2016
2	Alanine Transaminase (SGPT)IBA 01/2018 - 10/2008
2	Carbon MonoxideIBA 01/2017 - 01/2015
2	CitrullineIBA 10/2015 - 02/2012
2	ImmunosorbentsIBA 08/2015 - 07/2011
2	Collagen Type II (Type II Collagen)IBA 08/2015 - 01/2014
2	GadoliniumIBA 05/2015 - 10/2014
2	LipidsIBA 09/2014 - 08/2013
2	pyridinolineIBA 08/2013 - 07/2004
2	ResistinIBA 09/2011 - 07/2011
2	LeptinIBA 09/2011 - 07/2011
2	AdipokinesIBA 09/2011 - 07/2011
2	Interleukin-6 (Interleukin 6)IBA 09/2011 - 09/2004

Therapy/Procedure

29	Therapeutics 05/2022 - 04/2005
3	Remission Induction 01/2018 - 09/2012
3	Injections 10/2010 - 09/2006
2	Biological Therapy 01/2017 - 03/2013